Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
Am J Gastroenterol. 2023 Feb 1;118(2):304-316. doi: 10.14309/ajg.0000000000002063. Epub 2022 Oct 12.
Symptoms of common mental disorders, such as anxiety or depression, are associated with adverse clinical outcomes in inflammatory bowel disease (IBD). We report trajectories of these symptoms in IBD, patient characteristics associated with different trajectories, and effects on healthcare utilization and prognosis.
We collected demographic, symptom, psychological, and quality-of-life data, with questionnaires at 3-month intervals, over 12 months of follow-up. We collected healthcare utilization and IBD outcomes through notes review. We compared characteristics of those with persistently normal or improving anxiety or depression scores with those with persistently abnormal or worsening scores and the number of flares, glucocorticosteroid prescriptions, escalations of therapy, hospitalizations, or intestinal resections due to IBD activity.
Among 771 and 777 patients, respectively, worsening or persistently abnormal anxiety or depression scores were associated with increased antidepressant (28.6% vs 12.3% anxiety, 35.8% vs 10.1% depression, P < 0.001) and opiate use (19.0% vs 7.8% anxiety, P = 0.001 and 34.0% vs 7.4% depression, P < 0.001), compared with those with persistently normal or improving scores. These individuals were also more likely to have been diagnosed with IBD in the last 12 months (16.3% vs 5.0% anxiety, P = 0.001, and 15.1% vs 5.5% depression, P = 0.006), to have clinically active disease at baseline (57.1% vs 26.6% anxiety and 71.7% vs 29.1% depression, P < 0.001) and lower quality-of-life scores ( P < 0.001). Individuals with worsening or persistently abnormal trajectories of anxiety or depression required significantly more outpatient appointments, radiological investigations, and endoscopic procedures for IBD-related symptoms.
In this 12-month follow-up study, patients with IBD with worsening or persistently high anxiety or depression scores were higher utilizers of health care but were not at an increased risk of future adverse disease outcomes.
焦虑或抑郁等常见精神障碍的症状与炎症性肠病(IBD)的不良临床结局相关。我们报告了 IBD 中这些症状的轨迹、与不同轨迹相关的患者特征,以及对医疗保健利用和预后的影响。
我们在 12 个月的随访中,每 3 个月收集一次人口统计学、症状、心理和生活质量数据,通过病历回顾收集医疗保健利用和 IBD 结果。我们比较了持续正常或改善的焦虑或抑郁评分与持续异常或恶化评分的患者特征,以及因 IBD 活动而出现的发作次数、糖皮质激素处方、治疗升级、住院或肠道切除的数量。
在分别为 771 例和 777 例的患者中,焦虑或抑郁评分恶化或持续异常与抗抑郁药(28.6%比 12.3%焦虑,35.8%比 10.1%抑郁,P<0.001)和阿片类药物使用(19.0%比 7.8%焦虑,P=0.001 和 34.0%比 7.4%抑郁,P<0.001)的使用增加相关,而与持续正常或改善评分的患者相比。这些人也更有可能在过去 12 个月内被诊断出患有 IBD(16.3%比 5.0%焦虑,P=0.001,和 15.1%比 5.5%抑郁,P=0.006),在基线时有临床活动疾病(57.1%比 26.6%焦虑和 71.7%比 29.1%抑郁,P<0.001)和较低的生活质量评分(P<0.001)。焦虑或抑郁轨迹恶化或持续异常的个体因 IBD 相关症状需要更多的门诊预约、放射学检查和内镜检查。
在这项为期 12 个月的随访研究中,IBD 患者的焦虑或抑郁评分恶化或持续较高,他们对医疗保健的利用更多,但未来发生不良疾病结局的风险并未增加。